AI assistant
Supriya Lifescience Limited Earnings Release 2026
59375_rns_2026-05-28_adab5210-cbbf-48a5-9546-6c2618c66e6b.pdf
Earnings Release
Open in viewerOpens in your device viewer
SUPRIYA LIFESCIENCE LTD.
Creating true values that bind global health
May 28, 2026
To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434
National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA
Dear Sir (s),
Subject: Newspaper Advertisement- Regulation 47 and Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
In terms of Regulation 30 read with Schedule III and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith newspaper advertisement published in Financial Express and Loksatta on Thursday, May 28, 2026, containing extract of Audited Financial Results for the quarter and year ended March 31, 2026.
You are requested to kindly take the same on record.
Thanking you,
Yours faithfully,
For Supriya Lifescience Limited
Prachi Suhas
Digitally signed by
Prachi Suhas Sathe
Date: 2026.05.28
15:43:20 +05'30'
Prachi Sathe
Company Secretary & Compliance Officer
Corporate office
: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507
Fax: +91 22 26860011
GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452
E-mail: [email protected]
Website: www.supriyalifescience.com
Factory
: A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299
Fax: +91 2356 272178
E-mail: [email protected]
GOVT. RECOGNISED EXPORT HOUSE
THURSDAY, MAY 28, 2024
WWW.FINANCIALEXPRESS.COM
FINANCIAL EXPRESS
MEDICAMEN BIOTECH LIMITED
Reg. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi, 110019 (India)
CIN: L74899DU1993PLC656584 Contact No.: 011-47589500
Website: www.medicamen.com Email: [email protected]
Statement of Address (National Income, Commercial & Consolidated) for the quarter and year ended on March 31, 2026
Based on the recommendation of Audit Committee, the Board of Directors of the Company, at their meeting held on May 27, 2026, approved the audited financial results (Standalone & Consolidated) of the Company for the quarter and year ended on March 31, 2026.
The financial results along with Independent Audit Report have been posted on the website of the Company at www.medicamen.com and can be accessed by scanning the QPI code given below:
Place: New Delhi
Date: 27.05.2026
For and on behalf of Board of Directors
Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Director
DIN: 56317960
BhanSafal
James Aadi with BhanSafal
DHANSAFAL FINSERVE LIMITED
(Formerly known as "Lutunata Media & Infra Limited")
Tel: 024, L031909615001PLC644004
Registered Office: G-1402, Litus Corporate Park, Garagan East, Mumbai, Maharashtra 400003; Phone No.: (22) 6856-8500/09/00; Email: [email protected] Website: www.dhansafal.com
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND
FINANCIAL YEAR ENDED MARCH 31, 2026
The Board of Directors of the Company, at its Meeting held on Wednesday, May 27, 2026 have, now also approved the Audited Financial Results of the Company, for the quarter and financial year ended March 31, 2026.
The results, along with the Audited Report thereon, have been posted on the Company's website at www.dhansafal.com/financials/read and on the website of the stock exchange where the Company's shares are listed i.e., at www.towindia.com.
Also, it can be accessed by scanning the QPI code.
Place: Mumbai
Date: May 27, 2026
For and on behalf of Audit
Chairperson and Managing Director
CIN: 56408107
Note: The above information is in accordance with BhanSafal's Financial Report 017-1 of the SNFE (Liahraj Chitrapati) and Business Report 016-2 of the SNFE (Liahraj Chitrapati) of the Company Management Group.
The report is in accordance with the following information:
| Report | Date | Amount |
|---|---|---|
| 1 | 27.05.2026 | 1,41,000.00 |
| 2 | 27.05.2025 | 1,41,000.00 |
The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The
| Report | Date | Amount |
|---|---|---|
| 1 | 27.05.2026 | 1,41,000.00 |
| 2 | 27.05.2025 | 1,41,000.00 |
The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The
| Report | Date | Amount |
|---|---|---|
| 1 | 27.05.2026 | 1,41,000.00 |
| 2 | 27.05.2025 | 1,41,000.00 |
The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The
| Report | Date | Amount |
|---|---|---|
MEDICAMEN BIOTECH LIMITED
The above information is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information: The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The report is in accordance with the following information. The
| Report | Date | Amount |
|---|---|---|
BANSFORM OF THE ISSUE
| BANSFORM OF THE ISSUE | |||||
|---|---|---|---|---|---|
| Keyline 1875-301 Financials, CHINSED PRINCE LIMITED DN L714003, 06077237124 Registered Office: G-1402, Litus Corporate Park, Garagan East, Mumbai, Maharashtra 400003; Phone No: (22) 6856-8500/09/00; Email: [email protected] Address: 011-47589500 Contact: 011-47589500 | Dunbar United 31-03-2026 Viverdata 43-03-2026 Budgeted to: 07-27-2026 Viverdata 43-03-2026 Budgeted to: 07-27-2026 | Dunbar United 31-03-2026 Viverdata 43-03-2026 Budgeted to: 07-27-2026 Viverdata 43-03-2026 Budgeted to: 07-27-2026 | Quartor 43-03-2026 Viverdata 43-03-2026 Budgeted to: 07-27-2026 Quartor 43-03-2026 | Quartor 43-03-2026 Quartor 43-03-2026 Quartor 43-03-2026 | Quartor 43-03-2026 Quartor 43-03-2026 Quartor 43-03-2026 |
SUPRIYA LIFESCIENCE LIMITED
CN No: L51900MH2008PLC160452
207/208, Litzay/Brewer, Sonawala Road, Garagan (East), Mumbai - 400063.
Tel No.: +91 22 40332727; E-mail: [email protected]; Website: www.supryalifescience.com
EXTRACT OF AUDITED STANDALOID FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026
| SUN. | Particulars | Quarter ended 31-03-2026 Audit# | Quarter ended 31-12-2025 Viverdata | Quarter ended 31-03-2025 Audited | Year ended 31-03-2025 Audited | Year ended 31-03-2025 Audited |
|---|---|---|---|---|---|---|
| 1 | Total revenue from operations | 2,765.28 | 2,064.40 | 1,841.09 | 8,279.75 | 6,964.85 |
| 2 | Net Profit/(Loss) for the period (before tax, Exceptional items) | 921.29 | 873.78 | 640.62 | 2,702.37 | 2,484.81 |
| 3 | Net Profit/(Loss) for the period (after Tax (after Exceptional items) | 921.29 | 669.20 | 640.62 | 2,747.79 | 2,484.81 |
| 4 | Net Profit/(Loss) for the period after Tax (after Exceptional items) | 742.29 | 496.75 | 503.82 | 2,091.33 | 1,879.58 |
| 5 | Total Comprehensive Income for the period (after tax) | 742.29 | 496.75 | 503.82 | 2,091.33 | 1,879.58 |
| 6 | Equity Share capital | 180.97 | 180.97 | 180.97 | 180.97 | 180.97 |
| 7 | Other Equity | 11,916.38 | 9,906.63 | |||
| 8 | Earning per share (of F.D.-each) (not annualised for the Quarters) | 1.8loss | 9.22 | 8.17 | 8.29 | 25.98 |
| 2. Diluted | 9.22 | 8.17 | 8.29 | 25.98 | 23.35 |
Notes:
a) The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 27, 2026.
b) The figures for quarters ended March 31, 2026 and March 31, 2025 are balancing figures between the audited figures in respect of the full financial year and published year to date unaudited figures up to the third quarter of the respective financial year, which were subjected to a limited Revenue by the Statutory Auditors.
c) The above is an extract of the detailed format of the Financial Results filed with the Stock Exchange, under Regulaten 33 of the SENI (Liahraj Chitrapati) and the Business Report of the Government of India, and the Department of Finance and the Government of India, and the Department of Finance and the Government of India, and the Department of Finance and the Government of India, and the Department of Finance and the Government of India, and the Department of Finance and the Government of India, and the Department of Finance and the Government of India, and the Department of Finance and the Government of India, and the Department of Finance and the Government of India.
SUPRIYA LIFESCIENCE LIMITED
CN No: L51900MH2008PLC160452
207/208, Litzay/Brewer, Sonawala Road, Garagan (East), Mumbai - 400063.
Tel No.: +91 22 40332727; E-mail: [email protected]; Website: www.supryalifescience.com
| BANSFORM OF THE ISSUE | |||||
|---|---|---|---|---|---|
| Keyline 1875-301 Financials, CHINSED PRINCE LIMITED DN L714003, 06077237124 Registered Office: G-1402, Litus Corporate Park, Garagan East, Mumbai, Maharashtra 400003; Phone No: (22) 6856-8500/09/00; Email: [email protected] Address: 011-47589500 Contact: 011-47589500 | Dunbar United 31-03-2026 Viverdata 43-03-2026 Budgeted to: 07-27-2026 Viverdata 43-03-2026 Budgeted to: 07-27-2026 | Dunbar United 31-03-2026 Viverdata 43-03-2026 Budgeted to: 07-27-2026 Viverdata 43-03-2026 Budgeted to: 07-27-2026 | Quartor 43-03-2026 Viverdata 43-03-2026 Budgeted to: 07-27-2026 Viverdata 43-03-2026 | Quartor 43-03-2026 Viverdata 43-03-2026 Budgeted to: 07-27-2026 Viverdata 43-03-2026 | Quartor 43-03-2026 Viverdata 43-03-2026 Budgeted to: 07-27-2026 Viverdata 43-03-2026 |
FINANCIAL EXPRESS
| 1 | Total revenue from operations | 2,765.28 | 2,064.40 | 1,841.09 | 8,279.75 | 6,964.85 |
|---|---|---|---|---|---|---|
| 2 | Net Profit/(Loss) for the period (before tax, Exceptional items) | 921.29 | 873.78 | 640.62 | 2,702.37 | 2,484.81 |
| 3 | Net Profit/(Loss) for the period (after Tax (after Exceptional items) | 921.29 | 669.20 | 640.62 | 2,747.79 | 2,484.81 |
लोकसत्ता
www.isea1111.com
विविधा
मुंबई, गुरुवार, १८ मे २०२६
लिहीली पवलक्रिया आरोब्याची तुल्यकिल्ली
आरोब्स वार्ता
यावि दिल्ली : सरकारी सशस्त्रपैग
युन, राहत अनुष्ठान यशस्वी
जीवनशैली, आईडीएम अहमद
'अब फुट'चे पहाट बखत आणि
राहत आई सर्वांना मानवी
परशक्तीच्या परिसरात शेती, गोद
आदिवार, मधुमानिया आणि
अरुणा यांच्यासह रक्कम अशा
सामान्य कृत्य आणि सर्वां लागू
रूपयांचे हे फायदे पंधर दिन करीत, परंतु
संबंधी सशक्त किंवा वैशिष्ट्य
पुरुष कन्या शेती आकारात
असणे शेती यावी. यशस्वी वर्ल्ड
डॉक्टरांसाठी आणि सर्वांनेच
आरोग्याद्वारे निरोगी पदार्थांच्या
अन्य माणसांचे अयशमणी आहेच.
राखी वाटेल
१९ वीं शतक्या, १९ वीं शतक्या मध्ये आरोग्य दिन भरपूर घालत केला
जाते. यशस्वी पदार्थांच्या
रूपय आणि गट कशा टाळायच्या
याबद्दल जागरूकता निर्माण करणे हा
याशीचा पडत आहेत दिन घालता
करण्यास उद्देश आहे.
परशक्तीच्यात राहत येण्याच्या
योख्या मोठ्या तुल्यांमध्ये हा रेशम
रोजगार ही रेशम आहे. यासाठी सर्वांना
सर्वात मोठ्या तुल्यांचा
विचार वाटेल.
शेवसेलाप्रलुखांचा पालिकेस विसर
ऐतिहासिक कल्पूच्या देखभाल कंकटात पुतळ्याचा तत्त्वजल्द लाठी
लोकसत्ता खास प्रतिबंधी
मुंबई : मुंबईत युनान क्लब म्हणून
अध्यक्ष असलेल्या खरुद्देश
निकलनशाळेत मुंबई महासभिमला
अशा खास कंकट दिवस शाळा
भेजणा आहे. यात या खास आणि
पुस्तकांच्या माहितीसारख्या
लोकांतील
विश्वासप्रमुख
काळातील प्रथम सभापुरुषांचा
समावेशीपणा माणसाचा मुद्दा मिळवेल
(वाचन) याची समज मिळते. यात
म्हणून
माजरा आणि मिळवेल (विच.)
महानंद लालचोय या
मुद्द्याला पालिका द्यायला लागेल.
शेवसेलाप्रलुखांचा पालिकेस विसर
ऐतिहासिक कल्पूच्या देखभाल कंकटात पुतळ्याचा तत्त्वजल्द लाठी
लोकसत्ता खास प्रतिबंधी
मुंबई : मुंबईत युनान क्लब म्हणून
अध्यक्ष असलेल्या खरुद्देश
निकलनशाळेत मुंबई महासभिमला
अशा खास कंकट दिवस शाळा
भेजणा आहे. यात या खास आणि
पुस्तकांच्या माहितीसारख्या
लोकांतील
विश्वासप्रमुख
काळातील प्रथम सभापुरुषांचा
समावेशीपणा माणसाचा मुद्दा मिळवेल
(वाचन) याची समज मिळते. यात
म्हणून
माजरा आणि मिळवेल (विच.)
महानंद लालचोय या
मुद्द्याला पालिका द्यायला लागेल.
शेवसेलाप्रलुखांचा पालिकेस विसर
ऐतिहासिक कल्पूच्या देखभाल कंकटात पुतळ्याचा तत्त्वजल्द लाठी
लोकसत्ता खास प्रतिबंधी
मुंबई : मुंबईत युनान क्लब म्हणून
अध्यक्ष असलेल्या खरुद्देश
निकलनशाळेत मुंबई महासभिमला
अशा खास कंकट दिवस शाळा
भेजणा आहे. यात या खास आणि
पुस्तकांच्या माहितीसारख्या
लोकांतील
विश्वासप्रमुख
काळातील प्रथम सभापुरुषांचा
समावेशीपणा माणसाचा मुद्दा मिळवेल
(वाचन) याची समज मिळते. यात
म्हणून
माजरा आणि मिळवेल (विच.)
महानंद लालचोय या
मुद्द्याला पालिका द्यायला लागेल.
शेवसेलाप्रलुखांचा पालिकेस विसर
ऐतिहासिक कल्पूच्या देखभाल कंकटात पुतळ्याचा तत्त्वजल्द लाठी
लोकसत्ता खास प्रतिबंधी
मुंबई : मुंबईत युनान क्लब म्हणून
अध्यक्ष असलेल्या खरुद्देश
निकलनशाळेत मुंबई महासभिमला
अशा खास कंकट दिवस शाळा
भेजणा आहे. यात या खास आणि
पुस्तकांच्या माहितीसारख्या
लोकांतील
विश्वासप्रमुख
काळातील प्रथम सभापुरुषांचा
समावेशीपणा माणसाचा मुद्दा मिळवेल
(वाचन) याची समज मिळते. यात
म्हणून
माजरा आणि मिळवेल (विच.)
महानंद लालचोय या
मुद्द्याला पालिका द्यायला लागेल.
शेवसेलाप्रलुखांचा पालिकेस विसर
ऐतिहासिक कल्पूच्या देखभाल कंकटात पुतळ्याचा तत्त्वजल्द लाठी
लोकसत्ता खास प्रतिबंधी
शेवसेलाप्रलुखांचा पालिकेस विसर
मुंबई : नॉवर
पुस्तकात लिहित
रायसर ( ८२ )
खरेद खेरावारी
मुंबईत लिहित
मुंबईल